ICR Announces Presenting Companies for Its 21st Annual Conference
Momentum Public Relations
Press Release: November 28, 2018
NEW YORK–(BUSINESS WIRE)–ICR, a leading strategic communications and advisory firm serving roughly 600 private and public company clients, today announced its preliminary list of presenting companies for its 2019 conference at the Grand Lakes Resort in Orlando, Florida. Public company presentations will take place on Monday, January 14th and Tuesday, January 15th, and private company presentations on Wednesday, January 16th
The ICR Conference, renowned for its dynamic and unique format, includes company presentations, breakout sessions, expert commentary and a multitude of networking opportunities. Specifically, the annual event brings together management teams from 150+ public and private growth companies, institutional investors, sell-side research analysts, private equity professionals, sponsoring investment bankers and select members of the media to discuss industry trends and forward strategies at the most critical time of the year.
“As we approach our 21st consecutive year, we remain committed to a conference platform that offers a unique opportunity to connect with the financial community and other key stakeholders,” said Tom Ryan, Chief Executive Officer, ICR. “We are excited to announce our preliminary 2019 presenters, a diverse group of both private and public companies that will offer vital insights on consumer trends as the New Year begins.”
Below is a preliminary list of public companies set to present at the 2019 conference:
- Abercrombie & Fitch (ANF)
- AgroFresh Solutions, Inc. (AGFS)
- American Eagle Outfitters, Inc. (AEO)
- American Vanguard Corporation (AVD)
- AMMO, Inc. (POWW)
- Aphria Inc. (APH.TO & APHQF)
- Aritzia (ATZ)
- ascena retail group, inc. (ASNA)
- At Home Group Inc. (HOME)
- Avon Products, Inc. (AVP)
- B&G Foods, Inc. (BGS)**
- Barfresh Food Group, Inc. (BRFH)
- BJ’s Wholesale Club (BJ)
- Bluegreen Vacations (BXG)
- Boot Barn (BOOT)
- Build-A-Bear Workshop, Inc. (BBW)
- Capital Park Holdings (LOGG)
- Carrols Restaurant Group, Inc. (TAST)
- Centric Brands Inc. (CTRC)
- Chico’s FAS Inc. (CHS)
- Chipotle Mexican Grill, Inc. (CMG)
- Chuy’s Holdings, Inc. (CHUY)
- Citi Trends, Inc. (CTRN)
- Crocs, Inc. (CROX)
- Cronos Group Inc. (CRON)
- Darden Restaurants, Inc. (DRI)
- Dave & Buster’s Entertainment, Inc. (PLAY)
- Del Frisco’s Restaurant Group, Inc. (DFRG)
- Del Taco Restaurants, Inc. (TACO)
- Delta Apparel, Inc. (DLA)
- Delta Galil Industries, LTD. (DELT)
- Denny’s Corporation (DENN)
- Destination XL Group, Inc. (DXLG)
- Dogness International Corporation (DOGZ)
- Domino’s Pizza (DPZ)
- Ecoark Holdings, Inc. (OTCQX:ZEST)
- El Pollo Loco, Inc. (LOCO)
- FAT Brands Inc. (FAT)
- Five Below, Inc. (FIVE)
- Floor & Décor Holdings, Inc. (FND)
- Fox Factory Holding Corp. (FOXF)
- Freshpet, Inc. (FRPT)
- Genesco Inc. (GCO)
- Genuine Parts Company (GPC)
- G-III Apparel Group, Ltd. (GIII)
- Goosehead Insurance, Inc. (GSHD)
- Green Thumb Industries (GTI)
- Green Dot (GDOT)
- GUESS?, Inc. (GES)
- Habit Restaurants Inc. (HABT)
- Helen of Troy Limited (HELE)
- Hudson Ltd. (HUD)
- IPic Entertainment (IPIC)
- J. Jill, Inc. (JILL)
- Kona Grill (KONA)
- Kornit Digital (KRNT)
- Landec Corporation (LNDC)
- Lands’ End (LE)
- Li & Fung (494 HK)
- Liberty Health Sciences (LHS)**
- LifeVantage Corporation (LFVN)
- Lifeway Foods, Inc. (LWAY)
- Limoneira Company (LMNR)
- lululemon athletica (LULU)
- MarineMax, Inc. (HZO)
- Medifast, Inc. (MED)
- MJardin Group (MJAR)
- Movado Group, Inc. (MOV)
- Noodles & Company (NDLS)
- Nu Skin Enterprises, Inc. (NUS)
- Ollie’s Bargain Outlet Holdings, Inc. (OLLI)
- Oxford (OXM)
- Party City Holdco Inc. (PRTY)
- Performance Food Group Company (PFGC)**
- PetIQ, Inc. (PETQ)
- Planet Fitness (PLNT)
- Prestige Consumer Healthcare Inc. (PBH)
- Primo Water Corporation (PRMW)
- Purple Innovation, Inc. (PRPL)
- Reed’s, Inc. (REED)
- RiceBran Technologies (RIBT)
- Rocky Brands, Inc. (RCKY)
- RTW Retailwinds, Inc. (RTW)
- Ruth’s Hospitality Group, Inc. (RUTH)
- ServiceMaster Global Holdings, Inc. (SERV)
- Shake Shack Inc. (SHAK)
- ShiftPixy, Inc. (PIXY)
- Shoe Carnival (SCVL)
- SpartanNash Company (SPTN)
- Sportsman’s Warehouse Holdings, Inc. (SPWH)
- SP Plus Corporation (SP)
- Stage Stores, Inc. (SSI)
- Stein Mart, Inc. (SMRT)
- Strauss Group (STRS IL)
- SunOpta Inc. (STKL)
- Sysco Corporation (SYY)
- Tailored Brands (TLRD)
- Texas Roadhouse, Inc. (TXRH)
- The Chefs’ Warehouse, Inc. (CHEF)
- The Children’s Place, Inc. (PLCE)
- The Lovesac Company (LOVE)
- The ONE Group Hospitality, Inc. (STKS)
- Tilly’s, Inc. (TLYS)
- Tilray, Inc. (TLRY)
- TILT (TILT)
- Titan Machinery Inc. (TITN)
- Tuesday Morning Corporation (TUES)
- Tupperware Brands Corporation (TUP)
- Urban Outfitters, Inc. (URBN)
- Vince Holding Corp. (VNCE)
- Waitr Holdings, Inc. (WTRH)
- Wingstop Inc. (WING)
- YETI (YETI)
- ZAGG Inc. (ZAGG)
- Zumiez, Inc. (ZUMZ)
**Attending Only
The following private companies are also set to present or attend at the upcoming conference with many more in attendance:
- AccelFoods
- ACE Cash Express
- AriZona Beverages
- Benihana Corporation
- Black Shamrock Partners
- Bluestone Lane
- BrightFarms
- Chicken Salad Chick
- City Winery
- CorePower Yoga
- Cryoshift Cryotherapy
- Dash Brands/Domino’s Pizza China
- DMA
- Dr. Martens
- eatsa
- Fat Tuesday
- Faherty Brand
- Farmwise LLC
- Fazoli’s
- Fogo de Chão
- FS Food Group
- Global Franchise Group
- Growpacker, Inc.
- Gusto
- hims
- Hydrofarm Holdings Group, Inc.
- iFLY Indoor Skydiving
- Jeni’s Splendid Ice Creams
- Joe & The Juice
- Lazy Dog Restaurant & Bar
- Mack Weldon
- Mavis Discount Tire
- MediaMath
- Meow Wolf
- Mile High Labs
- Mizzen+Main
- Nectar
- Oath Pizza
- OLAM Corp.
- Olo
- Paper Source
- Pari Passau
- Paytronix
- Pincho Factory
- Plate IQ
- Presto
- Punch Bowl Social
- Q Mixers
- r4 Technologies
- Ranir
- Restaurant Technologies
- Romano’s Macaroni Grill
- Scene75 Entertainment Centers
- Shoe Sensation, Inc.
- Souvla
- Spencer Spirit Holdings, Inc.
- STANCE
- Sterling Hospitality
- Terra’s Kitchen
- Thanx
- The Riddler
- thredUP
- Thunderbird Growth Corp.
- Tommy John
- Topgolf Entertainment Group
- Tophatter
- True Food Kitchen
- WellBiz Brands
- Wine.com
- Wolf & Shepherd, Inc.
- World of Beer Bar & Kitchen
- Xenial, Inc.
- Yumpingo
The event is by invitation only. To request an invitation, please visit http://www.icrconference.com or email info@icrconference.com. Follow the ICR Conference on Twitter at @ICRPR and join the conversation using the #ICRConference hashtag.
About The ICR Conference
The ICR Conference is a unique platform where public and private company management teams, institutional investors, sell-side research analysts, investment bankers, private equity professionals and select media connect and network with one another as the year begins. The event is one of the largest investment conferences of the year, featuring presentations by more than 150 public and private companies, with attendance regularly exceeding 2,300. For more information please visit http://www.icrconference.com.
About ICR
Established in 1998, ICR partners with companies to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Boston, San Francisco and Beijing. ICR also advises on capital markets transactions through its ICR Capital subsidiary. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.
- Published in Business, growpacker, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma Bolsters Intellectual Property Position and Product Pipeline
Momentum Public Relations
Press Release: November 27, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a non-binding term sheet (“Term Sheet“) to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications. Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition. These include IntellitabTM abuse deterrent technology, FlexitabTM breakable sustained release tablet technology and SmartCelleTM nano-technology. SmartCelle’s ability to enhance the solubility of our THC and CBD products permits increased oral absorption and enables parenteral delivery. All platforms are protected by patents in force globally.
The Proposed Joint-Venture will provide Tetra Bio-Pharma with:
- Increased intellectual property protection for products developed under the joint venture;
- Access to abuse deterrent technology to minimize non-medical use of cannabinoids;
- An enhanced development pipeline addressing new therapeutic areas;
- Opportunities for disease-appropriate delivery including intranasal and intravenous delivery; and
- Increased oral drug absorption with immediate and extended release products.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are extremely excited about the creation of this joint venture as Altus brings many advantages to the table that will benefit our patients, their care providers and add tremendous value to the products being developed together. Their drug delivery technology will significantly strengthen our intellectual property portfolio.”
The White House Executive Office of the President of the United States along with several U.S. Federal agencies are encouraging pharmaceutical manufacturers to develop abuse-deterrent technologies. The Altus intellectual property will allow Tetra to bring formulations containing THC to market with a product label that clearly indicates its abuse-deterrence feature.
“This will be a major breakthrough for marketing THC drugs with opioid reduction claims at a time when society and the medical community are battling the epidemic abuse of opioids,” said Dr. Chamberland.
“We were highly impressed by Tetra’s science-driven approach to cannabinoid research and their proven ability to develop valuable medicines in this largely untapped new space,” said Dr. Damon Smith, CEO of Altus Formulation. “We greatly look forward to working with them and to bringing a range of life-changing new products to our patients.”
About Altus Formulation Inc.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost effective new products for its partners and their patents. With a focus on safer to use formulations, Altus’ technologies also include SmartCelle technologies for intravenous or oral delivery of low solubility large and small molecules.
For more information, please visit www.altusformulation.com
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Altus Formulation Inc.
Damon Smith
CEO
514-883-3447
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Crop’s ‘The Park’ Cannabis Farm Entering Sales Phase in ‘Major Step Forward’
Momentum Public Relations
Press Release: November 27, 2018
Crop Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that its tenant at the greenhouse complex known as ‘The Park’, situated in Wheeler Park, Washington State, has submitted several strains of finished cannabis flower to quarantine as harvest continues.
Once the certificates of analysis are received the finished cannabis will be sold to licensed cannabis retailers. The company is currently accumulating inventories of the following strains:
9 LB HAMMER BANANA KUSH DARTH VADER DUTCH HAWAIIN GHOST TRAIN GORILLA GLUE JUGGERNAUT PITBULL SOUR DIESEL STAR KILLER THC BOMB WA WOO TIFFANY CBD
The Park’s 35,000 square foot cannabis greenhouse recently underwent a complete retrofit for hydroponic automation and the addition of 500 Gavita HPS grow lights. It has five flowering bays and is sited on nine acres with full scale production estimated at approximately 12,000 pounds of high-quality cannabis annually (about 1,000 pounds per month). The operating costs are about $50,000 (U.S.) per month.
CROP CEO, Michael Yorke, stated: “CROP has finished cannabis at two of its tenant farms and which have entered the sales cycle in Washington, which is a major step forward. I cannot over stress the importance of the purity of tenant products. By only using organic inputs on our farms, CROP is utterly dedicated to providing the cleanest and most natural cannabis for the end user, who, I am sure, will appreciate the quality and taste the difference of the products.”
Furthermore, the company is pleased to announce it has settled $883,500 in debt by the issuance of shares of the company at $0.30 per unit. Each unit has one common share and one commons share purchase warrant exercisable at $0.50 for a period of 18 months following the issuance date.
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Cannadrink Beverage; the technological effects of Cannadrink Beverage; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Phone: (604) 484-4206
Website: http://www.cropcorp.com
- Published in Business, CROP Infrastructure, Life Sciences, Marijuana, Medical Marijuana, News Home
Growpacker Inc. Welcomes Blue Moon Founder Keith Villa as a Strategic Advisor
Momentum Public Relations
Press Release: November 26, 2018
Growpacker Inc. (“Growpacker” or the “Company”), a contract manufacturer of various THC and CBD infused edibles and beverages in the United States, is pleased to welcome Keith Villa as a strategic advisor to the company.
Keith created Blue Moon Brewing Company in 1995 as an operating unit of Coors Brewing Company, which later became MillerCoors. Keith is a third generation Coloradan with a Ph.D. in brewing science from the University of Brussels, a degree held by only a handful of people in the world.
Blue Moon’s Belgian White Ale, garnished by a Valencia orange slice, grew to become the #1 selling craft beer in the United States. During this time, Keith became a well-known brewmaster in the industry, appearing in Blue Moon advertisements, hosting beer events & dinners, serving as a celebrity & judge at beer competitions, and appearing in numerous brewing articles.
In early 2018, Keith retired from MillerCoors after 32 years and co-founded CERIA, Inc. (dba CERIA Brewing Company) with his wife, Jodi Villa. Their plan was to create an extraordinary cannabis infused de-alcoholized craft beer with THC that offered a similar onset time as alcohol. Fast-forward just 10-months later, and they have done exactly that with the Colorado launch in mid-December of CERIA’s Grainwave Belgian-Style White Ale with 5mg of THC, which will be followed by two additional styles and strengths in 2019 – an American Light Lager (2.5mg THC) and an IPA (10mg THC). These products will only be available to adult consumers 21 and up.
“We are very excited to have Keith join the team as a strategic advisor”, said Stephen Boyd, Chief Executive Officer of Growpacker. “The addition of Keith is instrumental to our company, as we believe that his experience will play a key role in developing the de-alcoholized THC-infused beverage segment, which is expected to become one of the fastest growing segments in the industry.”
Growpacker Inc., through its interest in GP Holdings, LLC, has been constructing its flagship cannabis manufacturing facility in Desert Hot Springs, California. The facility is expected to house a versatile array of processing and packaging lines that can address a multitude of product categories, including beverages (carbonated or noncarbonated teas, coffees, kombuchas, waters, beers, wines, spirits, etc), edibles (cookies, brownies, gummies, hard candies, caramels, lollipops, chocolate bars, enrobed chocolates, etc), flower products (weighted quarters, eighths, pre-rolls, etc), and other one-off type products.
The facility has been built from the ground up to adhere to FDA standards in the anticipation of a federal legalization in the near future, and is located in a city where manufacturing taxes on cannabis related products are currently zero percent, giving Growpacker a substantial competitive advantage in the manufacturing space. Growpacker expects the facility to be fully constructed by the end of Q4 2018, and expects to be in full production by the start of Q1 2019.
“We are developing one of the most versatile cannabis manufacturing facilities in California, a key infrastructure component that will accelerate the entire industry,” said Stephen Boyd. “We aim to become the go-to end-to-end cannabis manufacturing arm, which will enable companies to bring new products and brands to market exponentially faster, cheaper, and easier. The addition of Keith will bring a layer of experience that’s second to none in the industry, which will directly translate into the de-alcoholized THC-infused beverage products that we manufacture.”
About Growpacker
Growpacker Inc. is a Canadian based company, which through its American interest in GP Holdings LLC, is engaged in expanding the ancillary side of the California cannabis industry. The company offers local and international brands key services, such as formulation, manufacturing, co-packing, and distribution for THC & CBD infused products.
- Published in Business, growpacker, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
Momentum Public Relations
Press Release: November 26, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Tetra Bio-Pharma is the only company in North America, in addition to GW Pharmaceuticals, to work with both the FDA and Health Canada on clinical trial programs investigating cannabis and cannabinoid-based products for medical use. Tetra is currently recruiting patients for several clinical trials, including advanced cancer pain and a head to head trial investigating cannabis versus fentanyl in the treatment of breakthrough cancer pain, with the ultimate goal of reducing opioid use.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of the products mentioned above and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
Momentum Public Relations
Press Release: November 22, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a source of supply for a specialized cannabis smoke air purifying system and a mask designed for law and emergency responders.
The parties are establishing a strategic alliance to develop a medical grade air purifier and mask that will address Health Canada, labour unions and public safety concerns surrounding exposure to the second-hand smoke of cannabis.
Tetra Bio-Pharma expects orders for the mask and air purifier from caregivers, medical institutions, law enforcement agencies and security services around the world.
“This technology will enable the consumers of a smokable cannabis product to take their medication in the privacy of their home or in a medical clinic while being cared for by their families, caregivers or medical personnel,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We have begun working with law enforcement representatives across the country to design a specialized mask that will alleviate the effects of second-hand smoke from cannabis while performing their duties.”
About Sirius Air Solutions Inc.
Sirius Air Solutions Inc. (SAS) is an ultra-specialized air cleaner and smoke extractor manufacturer aiming to provide efficient answers for the most demanding innovative markets. Moreover, we are specialized in particle ultra filtration of air as well as in the chemical air filtration for contaminants present in gaseous form. Our approach is based on a deep understanding of airborne contaminants in order to design unique devices that consistently strive to exceed the highest standards available to date. Every day, we challenge ourselves to offer the most effective solutions to meet the most demanding situations that are proposed.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
North Bud Farms Provides Corporate Update
Momentum Public Relations
Press Release: November 22, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.
Construction of our Cannabis Production Facility in Low, Quebec
NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.
Cannabis Act Application
Migration of the application to the Cannabis Licensing Tracking System (“CLTS”) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.
Update on Janey’s Inc. Acquisition
NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.
Corporate Initiatives
NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.
“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,” said Ryan Brown, CEO of North Bud Farms Inc.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Life Sciences, Marijuana, Medical Marijuana, News Home, NorthBud
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
Momentum Public Relations
Press Release: November 20, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing of a binding proposal (the “Proposal“) for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations. Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre. Their formulation expertise will enable Tetra to develop innovative products for future clinical trials.
The Proposed Transaction is expected to provide Tetra with:
- Exclusive access to a Health Canada licensed facility (DEL) to fabricate cannabis and cannabinoid drug products for Tetra and Panag’s development activities;
- Cannabis and cannabinoid drug product formulation expertise; and
- The ability to manufacture products for all its clinical trials and commercial launches.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders. We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016. Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs. This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor. Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.”
Dr. Chamberland further stated, “Tetra has already entered into various agreements to ensure the supply meets the demand for cannabis, THC and CBD-based products with partners including Aphria Inc., True North Cannabis, a USA-based synthetic cannabinoid manufacturer and a phytocannabinoid supplier. With the expected completion of the Panag acquisition, Tetra will become vertically integrated with drug development capabilities that range from discovery all the way through to commercial launch. Our partnerships with Genacol Corporation and Kombucha Baby Brewing Company and its partners provides Tetra with a global sales and distribution platform for the commercialization of OTC drug and wellness products. In addition, Tetra has also established distribution and sales agreements with two pharmaceutical companies for its PPP001 prescription drug product.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Canadian and US Cannabis Edibles and Consumer Products Market Set to Explode to US$ 4.1 Billion by 2022
Canopy Growth CEO Bruce Linton: “…related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol, sleep aids, appetite aids, sports drinks, medicines and pet care.”
If you can read them, the signs are there.
The marijuana edibles industry, that part of the recreational marijuana that be ingested as a candy, a chocolate, a candy bar or in a mixed drink or a beer is going to be huge and may very well eclipse that old standby the smokeable flower or bud.
During the summer ResearchAndMarkets predicted that the global cannabis infused edible products market would grow at an expected CAGR of 25.01% from 2018 to 2022. The infused beverage market would include CBD based
recovery drinks and tonics as well as potent THC infused beers.
An October 11, press release announcing a new report, “The Tasty Future of Cannabis Edibles,” by BDS Analytics and Arcview Research predicted that by 2022 the edibles market would exceed US$4.1 billion, up from US$1.5 billion, for the Canadian and US market in 2018.
A June article in Forbes ran the headline “New Data Shows that Smoking Marijuana is a Dying Trend.” The data it references is the 2018 Deloitte report on the emerging Canadian marijuana market and the Forbes story says, A recent analysis from Deloitte shows that “smokable marijuana” in the northern nation will generate in upwards of $5 billion in 2019. But the edibles sector is predicted to hit somewhere between $12 and $22 billion by the time the market is in full swing.”
According to the BDS and Arcview report the THC infused candy and chocolate market segment took the lion’s share of the US market at 60%. The press release quotes Troy Dayton the CEO of ArcView Market Research: “Established big brand food and beverage companies are beginning to take notice of the cannabis edibles market and this is likely just the tip of the iceberg.”
If anyone doubts that edibles and beverages are the next big thing they should remember Constellation Brands $4 billion investment in Canopy Growth. Of course if that doesn’t convince you then there is also the partnering dance between Coca-Cola and Aurora that somehow didn’t get off the ground. Just how big the market is going to be is still up for grabs.
In a video on TheStreet.com, Canopy Growth CEO Bruce Linton claimed that related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol sleep aids appetite aids sports drinks and medicines and pet care.
If you think the $500 billion figure was a bit too high Constellation Brands COO Bill Newlands predicted that the legal cannabis product market would hit $200 billion plus. “Our View is that in the next ten plus years, this is going to be a $200 billion business worldwide. And some would argue that’s understating the case.”
It’s not difficult to see why the edibles market segment is going to take off.
Smoking is, after all, bad for you. The more difficult question to answer maybe how to profit from what will be a long term market build out and development, one that, ResearchAndMarkets.com has predicted will grow at an astonishing rate of 25.91% CAGR for the years 2018-2022. At the moment almost every major Canadian marijuana company has either a beverage in development or edibles underway in a test kitchen. Edibles and beverages are made from oils and compounds removed from the plants by volatile or non-volatile extraction methods. One way of investing in this developing market lies in investing in those companies that are extracting THC and CBDs from marijuana and then selling it business to business for use in either medical marijuana or as food grade marijuana.
North Bud Farms (CSE: NBUD) is building out its 95 acre site in Low Quebec where it is in within 10 km of a major hydro power plant. Construction is scheduled to be finished Q1 2019 and at the moment is on time and within budget.
The company is also in the process of applying of for a production license under the Access to Cannabis for Medical Purposes Regulation (ACMPR). North Bud has cleverly tagged itself as Marijuana 2.0, in reference to the second wave of legal marijuana slated for October 2019, when the edibles and infused beverage market will be open for business. The company’s strategy is to supply two underserved markets by producing and selling certified pharmaceutical grade cannabis and GMP standard raw cannabis for the food and beverage industry. The company also intends to develop and market new products.
To that end it has recently signed a number of agreements that will help turn its words into action. On September 27, 2018 the company announced that it had signed an agreement with American firm Made By Science to license its cannabinoid infusion technology for food and beverage platform.
On October 17, 2018 North Bud announced that it had created a distribution company, “1017,” so named to commemorate the date of marijuana legalization Canada, and signed a letter of intent to acquire Janey’s, one of the six licensed marijuana accessory distributers in Ontario. Janey’s is also engaged in marijuana product development. North Bud intends to develop multiple products over a variety of product segments under the 1017 brand.
As of November 15, 2018 North Bud Farms, (CSE: NBUD) was trading at $0.25.
Given the predicted explosion in the marijuana consumables and edibles market laying a bet or two on companies in that field makes sense and one such company that bears keeping an eye on is Arev Brands International (CSE: AREV), formally Arev Nutrition Sciences. Arev originally saw life as a developer and marketer of coconut oil based health products. It is focussed on two distinct market sectors, consumer products and manufacturing as an ingredients supplier. Along the way the company also developed a unique extraction technology and this is where they fit into the consumables market segment.
In a press release on Bloomberg the company announced that it had reached a major milestone in extraction development with its partner Alternative Extracts Inc. Using its proprietary extraction system Arev has developed a
system that preserves flavour and aroma and which in the case of beverages may lengthen shelf life. It intends to manufacture finished oil products with proprietary strains bred to specifically address key health issues: anxiety, pain management, central nervous system disorders, insomnia and libido.
Arev also has an exclusive distribution agreement with the award winning full line of BARE Topical products.
In September 2018 the company completed its acquisition of BC Bud Depot. BCBD has one of the world’s largest cannabis seed banks. Over the last 14 years BCBD has won over 40 awards and was the first Canadian company to win an international award with “BC God Bud,” now Canada’s most award winning strain of all time.
On November 15, 2018 AREV was trading at $0.365.
This blog should not be construed as investment advice. Every investor is obligated to perform his or her own due diligence. In the interests of transparency Arev and North Bud Farms are both Momentum Public Relations clients.
- Published in AREV Nutrition Sciences, Blog, Marijuana, Medical Marijuana, NorthBud
AREV Brands International Ltd. announces Success in Terpene Blends on 1st Degree Burns and Insect Bites
Momentum Public Relations
Press Release: November 14, 2018
AREV Brands International Ltd. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce AREV Brands International Ltd. has has reached another major milestone in one of its several joint development projects with Alternative Extracts Inc. Further to the research work reported on September 20, 2018, terpenes from non-regulated sources were used to formulate a proprietary composition for burns and insect bites. As noted in peer-reviewed literature, terpene synthesis is vital for cannabinoid synthesis as it provides the GPP molecule for CBGA synthesis.
As evidenced in these images (which was first taken within 18 hours of the burn accident, and in 24-hour succession thereafter), the blisters from the burn were completely eliminated within 4 days from the first application. The patient in this case is a 50-year old woman who has a known history of keloid formation. It is noted that the patient did not develop any infection.
AREV extracted the valuable terpenes from selected non-regulated plant materials and exudates from trees using its extraction systems that it acquired from Alternative Extracts Inc. The composition was formulated in collaboration between AREV and AEI. The mechanism of the composition is believed to be the result of the poly-molecular function of the terpenes.
The company cautions, that although these results are encouraging, a wider sample population is required. A formal study will be conducted in the coming months.
Burn data from World Health Organization shows that:
- – In India, over 1,000,000 people are moderately or severely burnt every year.
– Nearly 173,000 Bangladeshi children are moderately or severely burnt every year.
– In Bangladesh, Colombia, Egypt and Pakistan, 17% of children with burns have a temporary disability and 18% have a permanent disability.
– Burns are the second most common injury in rural Nepal, accounting for 5% of disabilities.
– In 2008, over 410,000 burn injuries occurred in the United States of America, with approximately 40,000 requiring hospitalization.
Mike Withrow commented “Although we are pleased to have been able to minimize the pain and scarring in this burn patient, the results from the use of our proprietary blend of natural compounds warrants further testing and trials.”
Dr. Adrian Wade, Chief Science Officer, of Alternative Extracts Inc. commented, “This collaboration continues to produce highly effective compounds and formulations. Terpenes have demonstrated to play an important role in an increasing number of natural health and medical products.”
Seek safe harbor and forward looking statements.
For further information, contact Mike Withrow, mike.withrow.vn@gmail.com, (778) 896-6536?.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
- Published in AREV Nutrition Sciences, Business, Life Sciences, Medical Marijuana, News Home, Technology